Navigation Links
ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

IRVINE, Calif., Sept. 6, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC) announced today that its Chief Executive Officer, Frank L. Jaksch, Jr., will be presenting the company's business strategy and growth opportunities at the 2011 Rodman & Renshaw Annual Global Investment Conference. The event will be held September 11-13, 2011 at the Waldorf Astoria in New York City.

ChromaDex is scheduled to make its presentation on Tuesday, September 13th at 11:30 a.m. local time. The company's presentation is currently available on its website, www.chromadex.com. For further details about the conference, please visit http://www.rodmanandrenshaw.com/conferences?id=162.

For more information about ChromaDex Corporation, visit www.chromadex.com and www.pteropure.com.

About ChromaDex®

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought ag
'/>"/>

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex Announces 2008 Year End Financial Results
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
5. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
6. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
7. InterMune to Present at Canaccord Adams Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. Bionovo to Present at Canaccord Adams Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 The American Brain Tumor Association (ABTA) ... Discovery Research Grant program. LOIs are due no later ... Discovery Grants are one-year, $50,000 grants that ... change current diagnostic or treatment paradigms for adults and ... research at its earliest stages, in the hopes that ...
(Date:9/1/2015)... ... ... In her thought provoking debut novel ‘ Ebola Vaccine Wars ’ (eBookIt.com; ... an Ebola pandemic that is on the cusp of wiping out humanity. Venice introduces ... counterterrorism, and who continues to appear in this series of books by Venice. ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... biopharmaceutical companies in the neuro and pain management space join prominent academics and ... Martin Conference Center at Harvard Medical School in Boston. , Neuro Advance ...
(Date:9/1/2015)... ... September 01, 2015 , ... A ... discovered by researchers at the Keck Graduate Institute and its collaborators. The discovery ... The findings were published online on August 27 by Scientific Reports, an open ...
Breaking Biology Technology:American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
... ULURU Inc. (NYSE Amex: ... the treatment of wounds using Altrazeal(TM) along with pre-clinical and ... at the annual Society for Advance Wound Care Conference ("SAWC") ... clinical evidence and data will be presented on posters on ...
... (Nasdaq: ANDS ), a biopharmaceutical company dedicated ... the areas of hepatitis C and oncology, today reported ... ended March 31, 2009. "We have now concluded three ... HCV patients that demonstrated potent antiviral activity over three ...
... N.J., April 23 Wyeth (NYSE: WYE ... of its outstanding $2 Convertible Preferred Stock, par value ... July 15, 2009 (the "Redemption Date"). As of ... Preferred Stock outstanding.The redemption price for each share of ...
Cached Biology Technology:ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009 2Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 8Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 9Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 10Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... Researchers in Australia are developing diversionary tactics to ... those responsible for major gut infections, such as cholera, ... to complex sugar receptors displayed on the surface of ... Society for General Microbiology,s meeting at Heriot-Watt University, Edinburgh, ...
... fat removed during liposuction conceal versatile cells that are ... stem cells, or iPS cells, than are the skin ... new study from Stanford,s School of Medicine. "We,ve identified ... co-author of the research, Michael Longaker, MD, who has ...
... Bacteria that generate significant amounts of electricity could be ... remote environments or to convert waste to electricity. Professor ... bacteria with large numbers of tiny projections called pili ... power in fuel cells than bacteria with a smooth ...
Cached Biology News:Designing probiotics that ambush gut pathogens 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Request Info...
Biology Products: